Treatment of Latent Tuberculosis Infection in Children
Journal of the Pediatric Infectious Diseases Society2013Vol. 2(3), pp. 248–258
Citations Over TimeTop 17% of 2013 papers
Abstract
Treatment of latent tuberculosis infection (LTBI) is an effective way of preventing future cases of tuberculosis disease. We review pediatric and adult studies of LTBI treatment (isoniazid and rifampin monotherapy, isoniazid plus rifampin, isoniazid plus rifapentine, and rifampin plus pyrazinamide). Based upon this review and our pediatric experience, we can offer recommendations for routine (isoniazid) and alternative courses of therapy.
Related Papers
- → Low Isoniazid Concentrations and Outcome of Tuberculosis Treatment with Once-Weekly Isoniazid and Rifapentine(2003)192 cited
- → Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis(2012)160 cited
- → Short-Course Therapy with Daily Rifapentine in a Murine Model of Latent Tuberculosis Infection(2009)72 cited
- → Quantification of pyrazinamide, isoniazid, acetyl‐isoniazid, and rifampicin by a high‐performance liquid chromatography method in human plasma from patients with tuberculosis(2020)19 cited
- → Effect of Pyrazinamide on Antimicrobially Active Serum Isoniazid(1960)